ชื่อเรื่อง : Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression

ชื่อผู้แต่ง : Fang Liu, Aifang Xu, Yan Zhang, Weiling Xuan, Tingbo Yan, Kenv Pan, Wenyan Yu, Jun Zhang

สำนักพิมพ์ : ELSEVIER

เนื้อหาโดยย่อ : Abstract: Objectives
To explore the epidemiological information, clinical characteristics, therapeutic outcomes and temporal progression of laboratory findings in 2019-coronavirus disease (COVID-19) patients exposed to lopinavir.
Methods
We collected data from ten COVID-19 patients admitted between January 22, 2020 and February 11, 2020 at Xixi hospital in Hangzhou, China.
Results
Of ten patients, secondary, tertiary and quartus patients emerged, the incubation period was 3–7 days. Mainly initial symptoms were cough and low fever (37.3–38.0 ℃). An asymptomatic case presented normal radiography, the others existed ground glass opacities. All cases (three transferred, seven discharged) exposed to lopinavir on initial hospitalization. Three patients stopped lopinavir using because of adverse effect, two of them deteriorated, one hospitalized longer than others who with sustained lopinavir using. Levels of potassium, albumin, lymphocyte were low, but increased persistently after treatment. Eosinophil values were low on initial hospitalization, then all returned to normal before discharge. Viral load of SARS-CoV-2, radiography and eosinophil improved continuously in 3–14, 6–8 and 7–9 days, respectively.
Conclusions
Increasing eosinophils may be an indicator of COVID-19 improvement. The COVID-19 patients may benefit from sustained lopinavir using. More researches on a larger scale are needed to verify these points.